TREML1 Activators
Activators of TREML1, a triggering receptor expressed on myeloid cells 1, function through various signaling pathways, influencing the receptor's modulation of innate immune responses. Direct activators would engage with TREML1 itself, initiating signaling cascades by directly binding to the receptor or affecting its ligand-receptor interactions. Such activators might include specific antibodies or ligands that target TREML1, leading to receptor dimerization, phosphorylation, or other post-translational modifications that foster signaling processes. These direct interactions could potentially alter the receptor's conformation, promoting the engagement with downstream signaling molecules and thus facilitating the receptor's role in cellular activation, phagocytosis, or cytokine release. The precise molecular changes induced by direct activators would depend on the structural affinity and binding kinetics specific to TREML1, which would govern the intensity and duration of the cellular responses initiated by the receptor.
Indirect activators, on the other hand, exert their influence on TREML1 by modulating other molecular pathways that intersect with or regulate the receptor's function. Such compounds might affect transcription factors like NF-κB, which plays a critical role in the expression of immune response genes, including those encoding TREML1. Inhibition of NF-κB could lead to a compensatory upregulation of TREML1 expression as the cell seeks to maintain immune homeostasis. Alternatively, compounds altering intracellular signaling kinases, such as PI3K, MAPK, or JAK, could impact TREML1 activity. The inhibition of these kinases might result in altered cytokine profiles and immune cell responses, potentially enhancing the functional role of TREML1 within the immune network. The secondary alterations in cellular signaling pathways could lead to changes in the expression levels, cellular localization, or activation state of TREML1, ultimately modulating the receptor's contribution to innate immunity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is known to irreversibly inhibit NF-κB activation by blocking phosphorylation of IκBα, leading to the inhibition of the NF-κB signaling pathway. This could lead to a compensatory upregulation of TREML1 activity as part of the immune system's adaptive response. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which could lead to altered cellular responses in the immune system. This may indirectly enhance the activity of TREML1, which is involved in the modulation of immune responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, potentially affecting cytokine synthesis and reducing inflammation. TREML1, involved in immune system signaling, could be indirectly activated due to alterations in the inflammatory response impacted by p38 MAPK inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which influences inflammatory responses and apoptosis. Indirectly, this could lead to an upregulation or enhancement of TREML1's role in immune signaling as a counter-regulatory mechanism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 acts as a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). This could indirectly increase TREML1 functional activity by affecting cellular stress response mechanisms that interact with TREML1. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD-0354 is an inhibitor of IKKβ, thereby blocking NF-κB activation. This could lead to indirect enhancement of TREML1 activity by altering the immune response due to the inhibition of a key transcription factor involved in inflammatory processes. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra is an IL-1 receptor antagonist that could indirectly affect TREML1's activity by modulating the immune response through its effect on interleukin-1 signaling, a pathway known to intersect with TREML1-involved processes. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a selective JAK1 and JAK2 inhibitor, which might indirectly enhance TREML1's activity by altering cytokine signaling and immune response modulation, pathways that TREML1 is involved with. | ||||||
Apocynin | 498-02-2 | sc-203321 sc-203321A sc-203321B sc-203321C | 1 g 10 g 100 g 500 g | $27.00 $68.00 $116.00 $360.00 | 74 | |
Apocynin inhibits NADPH-oxidase, potentially reducing the production of reactive oxygen species (ROS) that are involved in inflammatory signaling. This might lead to an indirect enhancement of TREML1's activity by modulating the oxidative stress response. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits NF-κB and is known for its anti-inflammatory properties. It could indirectly enhance TREML1's activity by modulating inflammatory signaling pathways, which could upregulate TREML1 as part of a compensatory immune response mechanism. | ||||||